Overview
NICE was unable to make a recommendation about the use in the NHS of ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy because no evidence submission was received from Janssen-Cilag.
Last reviewed: 22 March 2017
Next review: We will review this decision if the company decides to make a submission.